Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.52+0.03 (+2.01%)
Close on Nov 12, 2026Market cap $6.80MP/E –Yield –
Enveric Biosciences total assets
Total assets on the balance sheet at the end of each period.
Enveric Biosciences's total assets was $8.94M at Jun 30, 2026. For fiscal 2025 it was $5.10M, up 65.3% from the year before. Over ten years it grew -9.5% a year on average. The highest annual figure on record is $52.20M in fiscal 2017.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.10M | +65.3% |
| FY2024 | Dec 31, 2024 | $3.08M | -28.3% |
| FY2023 | Dec 31, 2023 | $4.30M | -78.0% |
| FY2022 | Dec 31, 2022 | $19.55M | -26.8% |
| FY2021 | Dec 31, 2021 | $26.72M | +552.2% |
| FY2020 | Dec 31, 2020 | $4.10M | +3665.9% |
| FY2019 | Dec 31, 2019 | $108.79K | -99.6% |
| FY2018 | Dec 31, 2018 | $29.64M | -43.2% |
| FY2017 | Dec 31, 2017 | $52.20M | +32.1% |
| FY2016 | Dec 31, 2016 | $39.51M | +185.6% |
| FY2015 | Dec 31, 2015 | $13.83M | +271973.4% |
| FY2014 | Dec 31, 2014 | $5.09K | +13.8% |
| FY2013 | Dec 31, 2013 | $4.47K | -20.2% |
| FY2012 | Dec 31, 2012 | $5.60K | -75.1% |
| FY2011 | Dec 31, 2011 | $22.45K | +1893.8% |
| FY2010 | Dec 31, 2010 | $1.13K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.94M | +152.1% |
| Q1 FY2026 | Mar 31, 2026 | $5.52M | +8.2% |
| Q4 FY2025 | Dec 31, 2025 | $5.10M | +65.3% |
| Q3 FY2025 | Sep 30, 2025 | $4.36M | -8.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.55M | -41.4% |
| Q1 FY2025 | Mar 31, 2025 | $5.10M | -42.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.08M | -28.3% |
| Q3 FY2024 | Sep 30, 2024 | $4.79M | -27.6% |
| Q2 FY2024 | Jun 30, 2024 | $6.05M | -38.3% |
| Q1 FY2024 | Mar 31, 2024 | $8.85M | -44.2% |
| Q4 FY2023 | Dec 31, 2023 | $4.30M | -78.0% |
| Q3 FY2023 | Sep 30, 2023 | $6.62M | -78.5% |
| Q2 FY2023 | Jun 30, 2023 | $9.80M | -65.7% |
| Q1 FY2023 | Mar 31, 2023 | $15.85M | -50.7% |
| Q4 FY2022 | Dec 31, 2022 | $19.55M | -26.8% |
| Q3 FY2022 | Sep 30, 2022 | $30.86M | -55.8% |
| Q2 FY2022 | Jun 30, 2022 | $28.57M | +20.6% |
| Q1 FY2022 | Mar 31, 2022 | $32.18M | +24.8% |
| Q4 FY2021 | Dec 31, 2021 | $26.72M | +552.2% |
| Q3 FY2021 | Sep 30, 2021 | $69.76M | +149.2% |
| Q2 FY2021 | Jun 30, 2021 | $23.69M | -13.9% |
| Q1 FY2021 | Mar 31, 2021 | $25.79M | -5.0% |
| Q4 FY2020 | Dec 31, 2020 | $4.10M | +3665.9% |
| Q3 FY2020 | Sep 30, 2020 | $27.99M | -6.0% |
| Q2 FY2020 | Jun 30, 2020 | $27.51M | +1.9% |
| Q1 FY2020 | Mar 31, 2020 | $27.14M | -11.0% |
| Q4 FY2019 | Dec 31, 2019 | $108.79K | -99.6% |
| Q3 FY2019 | Sep 30, 2019 | $29.79M | -35.1% |
| Q2 FY2019 | Jun 30, 2019 | $27.00M | -40.7% |
| Q1 FY2019 | Mar 31, 2019 | $30.51M | -36.3% |
| Q4 FY2018 | Dec 31, 2018 | $29.64M | -43.2% |
| Q3 FY2018 | Sep 30, 2018 | $45.90M | -2.6% |
| Q2 FY2018 | Jun 30, 2018 | $45.54M | -3.7% |
| Q1 FY2018 | Mar 31, 2018 | $47.92M | -3.5% |
| Q4 FY2017 | Dec 31, 2017 | $52.20M | +32.1% |
| Q3 FY2017 | Sep 30, 2017 | $47.14M | +23.6% |
| Q2 FY2017 | Jun 30, 2017 | $47.29M | – |
| Q1 FY2017 | Mar 31, 2017 | $49.68M | – |
| Q4 FY2016 | Dec 31, 2016 | $39.51M | – |
| Q3 FY2016 | Sep 30, 2016 | $38.12M | – |
See a number that looks wrong?